^
    Back
    Association details:
    Biomarker:FGF19 negative
    Cancer:Hepatocellular Cancer
    Drug:fisogatinib (BLU-554) (FGFR4 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    Cancer Discov
    Title:

    First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma

    Excerpt:
    For dose escalation, 25 patients received 140 to 900 mg fisogatinib once daily...Across doses, the overall response rate was 17% in FGF19-positive patients [median duration of response: 5.3 months (95% CI, 3.7-not reached)] and 0% in FGF19-negative patients.
    DOI:
    10.1158/2159-8290.CD-19-0555